| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1010614909 |
| P356 | DOI | 10.1007/S12265-010-9211-9 |
| P8608 | Fatcat ID | release_5g37366y4vg4bnddryswmgq7zu |
| P3181 | OpenCitations bibliographic resource ID | 3299815 |
| P932 | PMC publication ID | 2933808 |
| P698 | PubMed publication ID | 20645037 |
| P5875 | ResearchGate publication ID | 45276166 |
| P50 | author | Hugo A. Katus | Q27929168 |
| P2093 | author name string | David Rohde | |
| Mirko Voelkers | |||
| Patrick Most | |||
| Julia Ritterhoff | |||
| Thomas G Parker | |||
| P2860 | cites work | Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association | Q22306345 |
| Ca2+ -dependent interaction of S100A1 with the sarcoplasmic reticulum Ca2+ -ATPase2a and phospholamban in the human heart | Q24305007 | ||
| S100A1: a regulator of myocardial contractility | Q24555086 | ||
| Three-dimensional solution structure of the calcium-signaling protein apo-S100A1 as determined by NMR | Q27637285 | ||
| Structural and motional changes induced in apo-S100A1 protein by the disulfide formation between its Cys 85 residue and beta-mercaptoethanol | Q27649355 | ||
| Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type | Q28139003 | ||
| Transcriptional regulation of S100A1 and expression during mouse heart development | Q28139632 | ||
| S100A1, a new marker for acute myocardial ischemia | Q28142557 | ||
| Right ventricular upregulation of the Ca(2+) binding protein S100A1 in chronic pulmonary hypertension | Q28143987 | ||
| Intracellular and extracellular roles of S100 proteins | Q28184555 | ||
| Titin-actin interaction in mouse myocardium: passive tension modulation and its regulation by calcium/S100A1 | Q28188329 | ||
| S100A12 (EN-RAGE) in monitoring Kawasaki disease | Q28191511 | ||
| Understanding ATP synthesis: structure and mechanism of the F1-ATPase (Review) | Q28203942 | ||
| Extracellular S100A1 protein inhibits apoptosis in ventricular cardiomyocytes via activation of the extracellular signal-regulated protein kinase 1/2 (ERK1/2) | Q28205358 | ||
| Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance | Q28207738 | ||
| Impaired cardiac contractility response to hemodynamic stress in S100A1-deficient mice | Q28209366 | ||
| The small EF-hand Ca2+ binding protein S100A1 increases contractility and Ca2+ cycling in rat cardiac myocytes | Q28217246 | ||
| Ultrastructural distribution of the S100A1 Ca2+-binding protein in the human heart | Q28217514 | ||
| S100ao (alpha alpha) protein is mainly located in the heart and striated muscles | Q28235967 | ||
| Interaction of S100A1 with the Ca2+ release channel (ryanodine receptor) of skeletal muscle | Q28249011 | ||
| S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy | Q28249115 | ||
| S100A1 gene transfer: a strategy to strengthen engineered cardiac grafts | Q28256042 | ||
| S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes | Q28258841 | ||
| Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction | Q28261916 | ||
| S100A1: Structure, Function, and Therapeutic Potential | Q28263662 | ||
| S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction | Q28272699 | ||
| Distinct subcellular localization of calcium binding S100 proteins in human smooth muscle cells and their relocation in response to rises in intracellular calcium | Q28275090 | ||
| S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products | Q28276090 | ||
| S100A1 increases the gain of excitation-contraction coupling in isolated rabbit ventricular cardiomyocytes | Q28277947 | ||
| S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature) | Q28279641 | ||
| Titin-isoform dependence of titin-actin interaction and its regulation by S100A1/Ca2+ in skinned myocardium | Q28280473 | ||
| Hydrophobic residues in the C-terminal region of S100A1 are essential for target protein binding but not for dimerization | Q28287795 | ||
| Altered expression of the Ca(2+)-binding protein S100A1 in human cardiomyopathy | Q28295279 | ||
| Cardiac adenoviral S100A1 gene delivery rescues failing myocardium | Q28296403 | ||
| Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue | Q28300082 | ||
| Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: rationale for a new nomenclature of the S100 calcium-binding protein family | Q28301899 | ||
| Distinct subcellular location of the Ca2+-binding protein S100A1 differentially modulates Ca2+-cycling in ventricular rat cardiomyocytes | Q28302811 | ||
| The three-dimensional solution structure of Ca(2+)-bound S100A1 as determined by NMR spectroscopy | Q28575112 | ||
| Augmentation of Cav1 channel current and action potential duration after uptake of S100A1 in sympathetic ganglion neurons | Q28580012 | ||
| More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure | Q57396381 | ||
| Ca2+ /S100 regulation of giant protein kinases | Q57838277 | ||
| S-100ao protein in serum during acute myocardial infarction | Q68748465 | ||
| S100a0 (alpha alpha) protein: distribution in muscle tissues of various animals and purification from human pectoral muscle | Q68866362 | ||
| Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation | Q73010823 | ||
| S100A4 is upregulated in injured myocardium and promotes growth and survival of cardiac myocytes | Q80233959 | ||
| Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells | Q81144246 | ||
| S100B expression modulates left ventricular remodeling after myocardial infarction in mice | Q81378185 | ||
| The ischemic rat heart releases S100B | Q81793588 | ||
| S100A1: a calcium-modulating inotropic prototype for future clinical heart failure therapy | Q84631543 | ||
| Redox modifications of the C-terminal cysteine residue cause structural changes in S100A1 and S100B proteins. | Q30349807 | ||
| NO/redox disequilibrium in the failing heart and cardiovascular system | Q30475784 | ||
| Modular motif, structural folds and affinity profiles of the PEVK segment of human fetal skeletal muscle titin | Q31577644 | ||
| Immunocytochemical localization of S100A1 in mitochondria on cryosections of the rat heart | Q33292136 | ||
| S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+ handling, sarcomeric, and mitochondrial function | Q33757903 | ||
| beta-adrenergic receptor blockade in chronic heart failure | Q33831388 | ||
| S100 proteins: structure, functions and pathology | Q34625714 | ||
| ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology | Q34830023 | ||
| Cardiac energy metabolism homeostasis: role of cytosolic calcium | Q34977128 | ||
| Molecular mechanisms of S100-target protein interactions | Q35088392 | ||
| What is the role of beta-adrenergic signaling in heart failure? | Q35582718 | ||
| Calcium-dependent and -independent interactions of the S100 protein family. | Q36472950 | ||
| S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance | Q36801998 | ||
| A review of the S100 proteins in cancer | Q36848759 | ||
| Targeting myocardial beta-adrenergic receptor signaling and calcium cycling for heart failure gene therapy | Q36865884 | ||
| Treatment strategies for peripheral artery disease | Q37519704 | ||
| S100A1: a pluripotent regulator of cardiac and vascular function | Q37729863 | ||
| S100-mediated signal transduction in the nervous system and neurological diseases. | Q40371571 | ||
| Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products | Q42414162 | ||
| Lack of S100A1 in mice confers a gender-dependent hypertensive phenotype and increased mortality after myocardial infarction | Q42450906 | ||
| Endothelial S100A1 modulates vascular function via nitric oxide. | Q42525001 | ||
| Ca2+ -dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytes | Q42738033 | ||
| Isoproterenol-induced myocardial injury resulting in altered S100A4 and S100A11 protein expression in the rat. | Q43504846 | ||
| Regulation of the S100B gene by alpha 1-adrenergic stimulation in cardiac myocytes | Q44185618 | ||
| S100A6 is a negative regulator of the induction of cardiac genes by trophic stimuli in cultured rat myocytes | Q45225467 | ||
| Affinity of S100A1 protein for calcium increases dramatically upon glutathionylation | Q46483015 | ||
| A soluble protein characteristic of the nervous system | Q47721048 | ||
| S100a0 (alpha alpha) protein in cardiac muscle. Isolation from human cardiac muscle and ultrastructural localization | Q48122912 | ||
| The brain protein S-100ab induces apoptosis in PC12 cells | Q48136732 | ||
| Isolation of a rat S100α cDNA and distribution of its mRNA in rat tissues | Q48217089 | ||
| Rapid desensitization of PC12 cells stimulated with high concentrations of extracellular S100. | Q48238883 | ||
| Expression of members of the S100 Ca2+-binding protein family in guinea-pig smooth muscle | Q48410276 | ||
| Interaction of isoforms of S100 protein with smooth muscle caldesmon | Q48518541 | ||
| S100A1 gene transfer in myocardium. | Q50708011 | ||
| Increased serum levels and expression of S100A8/A9 complex in infiltrated neutrophils in atherosclerotic plaque of unstable angina. | Q53495274 | ||
| Co-expression/co-location of S100 proteins (S100B, S100A1 and S100A2) and protein kinase C (PKC-beta, -eta and -zeta) in a rat model of cerebral basilar artery vasospasm. | Q54631849 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | gene therapy | Q213901 |
| cardiovascular disease | Q389735 | ||
| transport protein | Q2111029 | ||
| nerve tissue protein | Q6996861 | ||
| biomedical investigative technique | Q66648976 | ||
| cardiovascular agent | Q50429907 | ||
| P304 | page(s) | 525-37 | |
| P577 | publication date | 2010-10-01 | |
| P1433 | published in | Journal of Cardiovascular Translational Research | Q6294906 |
| P1476 | title | S100A1: a multifaceted therapeutic target in cardiovascular disease | |
| P478 | volume | 3 |
| Q41844120 | An efficient expression and purification strategy for the production of S100 proteins in Escherichia coli |
| Q88674963 | Association between serum S100A1 level and Global Registry of Acute Coronary Events score in patients with non-ST-segment elevation acute coronary syndrome |
| Q37965045 | Cardiac gene therapy: from concept to reality |
| Q38506250 | Cardiomyocytes, endothelial cells and cardiac fibroblasts: S100A1's triple action in cardiovascular pathophysiology |
| Q48498411 | Functional evidence for an active role of B-type natriuretic peptide in cardiac remodelling and pro-arrhythmogenicity. |
| Q37001259 | Functions of S100 proteins. |
| Q36617570 | Gene targeting in ischemic heart disease and failure: translational and clinical studies |
| Q36698991 | Gene transfer for congestive heart failure: update 2013. |
| Q37683440 | Induction of microRNA-138 by pro-inflammatory cytokines causes endothelial cell dysfunction |
| Q42390071 | Inhibition of cardiac CaMKII to cure heart failure: step by step towards translation? |
| Q97529094 | Molecular Basis of S100A1 Activation and Target Regulation Within Physiological Cytosolic Ca2+ Levels |
| Q36678598 | Molecular Basis of S100A1 Activation at Saturating and Subsaturating Calcium Concentrations |
| Q36175406 | Myocardial infarction in a patient with left ventricular noncompaction: a case report. |
| Q35930186 | Neoinnervation and neovascularization of acellular pericardial-derived scaffolds in myocardial infarcts. |
| Q42128457 | Novel interactions of the TRTK12 peptide with S100 protein family members: specificity and thermodynamic characterization |
| Q27673395 | Post-translational S-Nitrosylation Is an Endogenous Factor Fine Tuning the Properties of Human S100A1 Protein |
| Q35603727 | Role of S100A1 in hypoxia-induced inflammatory response in cardiomyocytes via TLR4/ROS/NF-κB pathway |
| Q35911792 | S100 calcium binding proteins and ion channels |
| Q35206368 | S100 proteins in cancer |
| Q35879854 | S100A1 (S100 calcium binding protein A1) |
| Q36756998 | S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction. |
| Q39031292 | S100A1 and S100B: Calcium Sensors at the Cross-Roads of Multiple Chondrogenic Pathways |
| Q28240188 | S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4 |
| Q64256146 | S100A4 inhibits cell proliferation by interfering with the S100A1-RAGE V domain |
| Q50000872 | S100B as an antagonist to block the interaction between S100A1 and the RAGE V domain. |
| Q28259868 | Targeting S100A1 in heart failure |
| Q26822507 | Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial |
Search more.